MORTALITY BURDEN OF TRANSFUSION DEPENDENCY AND IRON OVERLOAD IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES.

被引：0
|
作者：
Arnan, M. [1 ]
Pomares, H. [2 ]
Esteban, L. [3 ]
Alonso, E. [4 ]
Pareja, L. [3 ]
Sanchez-Ortega, I. [2 ]
Fernandez de Sevilla, A. [2 ]
Ribes, J. [3 ]
Duarte, R. [1 ]
机构：
[1] Inst Catala Oncol, Hematol Dept, Lhospitalet De Llobregat, Spain
[2] Hosp Duran & Reynals, Inst Catala Oncol, Hematol Dept, Lhospitalet De Llobregat, Spain
[3] Inst Catala Oncol, Catalan Registry Canc, Lhospitalet De Llobregat, Spain
[4] Hosp Univ Bellvitge, PAtol Dept, Lhospitalet De Llobregat, Spain
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P199
引用
收藏
页码：86 / 86
页数：1
相关论文
共 50 条
  • [31] Impact of iron overload in myelodysplastic syndromes
    Fenaux, Pierre
    Rose, Christian
    BLOOD REVIEWS, 2009, 23 : S15 - S19
  • [32] Iron overload in myelodysplastic syndromes (MDS)
    Norbert Gattermann
    International Journal of Hematology, 2018, 107 : 55 - 63
  • [33] IRON CHELATION THERAPY IN TRANSFUSION-DEPENDENT MYELODYSPLASTIC SYNDROMES. RETROSPECTIVE STUDY OF 53 PATIENTS IN A SINGLE INSTITUTION
    Finelli, C.
    Clissa, C.
    Barraco, M.
    De Maio, C.
    Fogli, M.
    Stanzani, M.
    Parisi, S.
    Paolini, S.
    Bosi, C.
    Cavo, M.
    HAEMATOLOGICA, 2017, 102 : 57 - 57
  • [34] Iron Metabolism and Erythropoietic Stress in Myelodysplastic Syndromes.
    Santini, Valeria
    Sanna, Alessandro
    Duca, Lorena
    Gozzini, Antonella
    Girelli, Domenico
    Cortelezzi, Agostino
    Reda, Gianluigi
    Campostrini, Natascia
    Cappellini, Maria Domenica
    BLOOD, 2009, 114 (22) : 696 - 696
  • [35] Cost of transfusion dependency among managed care patients with myelodysplastic syndromes
    Frytak, J. R.
    Henk, H. J.
    de Castro, C. M.
    Halpern, R.
    Nelson, M.
    LEUKEMIA RESEARCH, 2007, 31 : S111 - S112
  • [36] Decreased Iron Overload and Oxidative Stress in Transfusion Dependent Patients with Myelodysplastic Syndromes (MDS) with the Oral Iron Chelator Deferiprone
    Merkel, Drorit
    Soffer, Shelly
    Filanovsky, Kalman
    Braester, Andrei
    Fibach, Eitan
    Dana, Mutaz Mohammad
    Ofran, Yishay
    Greenbaum, Uri
    Nagler, Arnon
    Mittelman, Moshe
    BLOOD, 2018, 132
  • [37] RISKS FOR INFECTION IN PATIENTS WITH MYELODYSPLASTIC AND MYELODYSPLASTIC/ MYELOPROLIFERATIVE SYNDROMES: IMPACT OF IRON OVERLOAD
    Orero, M. T.
    Javier, K.
    Villegas, C.
    Costa, S.
    Ortiz, S.
    Perez, P.
    Roig, M.
    Linares, M.
    LEUKEMIA RESEARCH, 2017, 55 : S148 - S149
  • [38] THE ORAL IRON CHELATOR DEFERIPRONE DECREASES IRON OVERLOAD AND OXIDATIVE STRESS IN TRANSFUSION DEPENDENT PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
    Merkel, D.
    Soffer, S.
    Filanovsky, K.
    Fibach, E.
    Dana, M.
    Mittelman, M.
    Nagler, A.
    Rachmilewitz, E. A.
    LEUKEMIA RESEARCH, 2017, 55 : S53 - S53
  • [39] PRACTICAL CONSIDERATIONS IN TREATING PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND IRON OVERLOAD
    McKiernan, Phyllis
    Shah, Jayshree
    ONCOLOGY NURSING FORUM, 2018, 45 (02)
  • [40] Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes
    Wimazal, F.
    Noesslinger, T.
    Baumgartner, C.
    Sperr, W. R.
    Pfeilstoecker, M.
    Valent, P.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2009, 39 (05) : 406 - 411
12345